The Gut-Skin Axis: How Your Microbiome Connects to Psoriasis

The gut-skin axis refers to the bidirectional communication network linking the intestinal microbiome to skin immunity and inflammation. It is not a new concept in basic science, but its clinical relevance to psoriasis has become substantially clearer over the past decade. The pathway operates through multiple overlapping mechanisms: gut bacteria influence systemic immune activation, modulate the production of short-chain fatty acids (SCFAs) that regulate T cell differentiation, affect intestinal permeability and bacterial translocation, and shape the balance of pro- versus anti-inflammatory cytokines circulating throughout the body.^[6]

In psoriasis, the inflammatory cascade is driven largely by the IL-23/Th17 axis—a signaling pathway that promotes hyperproliferation of keratinocytes and the characteristic plaque-forming skin lesions. What makes the gut-skin axis particularly relevant is that gut microbiota dysbiosis has been shown to directly activate and amplify this same pathway. When the intestinal barrier is compromised—a condition associated with dysbiosis—bacterial products including lipopolysaccharide (LPS) can enter systemic circulation, triggering dendritic cell activation and downstream Th17 responses that worsen skin inflammation.^[7]

Animal models have made this mechanistic link explicit: psoriasis-like pathology does not develop under germ-free conditions, and fecal microbiota transplantation from mice with severe psoriatic phenotypes has been shown to aggravate skin inflammation in mildly symptomatic recipients—alongside increased Th17 cell infiltration.^[6] While human studies are necessarily more complex, the direction of the evidence is consistent: gut microbial composition is not incidental to psoriasis. It is part of the disease biology.

What Gut Dysbiosis Looks Like in Psoriasis and PsA

Across multiple studies using 16S rRNA gene sequencing and metagenomic analyses, a consistent pattern of gut dysbiosis emerges in people with psoriasis compared with healthy controls. The changes are not random—they follow a recognizable immunological logic.^[8]

In patients with psoriasis and psoriatic arthritis, research documents reduced populations of bacteria associated with anti-inflammatory and barrier-protective functions: Bifidobacterium spp., Lactobacillus spp., Faecalibacterium prausnitzii, Parabacteroides, Coprobacillus, and Akkermansia muciniphila—a mucus-layer-protecting species that converts mucin into SCFAs. Simultaneously, potentially pathogenic species are overrepresented, including Salmonella sp., Campylobacter sp., Helicobacter sp., Escherichia coli, and Alcaligenes sp.^[9]

This depletion of SCFA-producing bacteria is particularly significant. SCFAs—including acetate, propionate, and butyrate—are potent immunomodulators. Research in animal models of psoriasis has shown that acetate and propionate levels are significantly inversely correlated with IL-17 and IL-23 concentrations: lower SCFA production means less suppression of the inflammatory signaling at the heart of psoriatic disease.^[7]

The gut dysbiosis found in psoriatic arthritis notably overlaps with that observed in inflammatory bowel disease (IBD)—a comorbidity that affects a meaningful proportion of PsA patients. The shared dysbiosis pattern suggests shared pathogenic mechanisms, and it partially explains why probiotic interventions developed in the IBD context have also been piloted in PsA.^[5]

For a broader look at how gut bacterial imbalances present systemically, our article on Lactobacillus deficiency signs and symptoms covers many of the overlapping clinical signals in detail.

How Probiotics May Modulate Psoriatic Inflammation

Probiotic bacteria do not simply "replace" depleted microbes and call it a day. Their mechanisms of action in the context of immune-mediated inflammatory diseases are multifaceted, and several are directly relevant to psoriasis pathology.

Research has identified at least four distinct mechanisms by which probiotic strains may benefit psoriasis and PsA patients:^[10]

1. Regulating intestinal inflammation and immune function. Probiotic genera including Lactobacillus and Bifidobacterium interact directly with mucosal immune cells, promoting tolerogenic dendritic cell phenotypes and regulatory T cell (Treg) activity. Tregs act as a counterbalance to Th17 cells, the primary drivers of psoriatic plaques. Bifidobacterium infantis 35624, for instance, has been shown to increase peripheral Treg populations while reducing pro-inflammatory cytokine output.^[4]

2. Preventing increased intestinal permeability and bacterial translocation. Leaky gut—increased intestinal permeability allowing bacterial products to reach systemic circulation—is consistently elevated in psoriatic arthritis patients. In a 12-week pilot study, all PsA participants showed elevated fecal zonulin (a permeability marker), which significantly correlated with peripheral Th17 cell frequency. After probiotic intervention, both zonulin levels and disease activity scores improved.^[5]

3. Reducing production of autoantibodies and pro-inflammatory cytokines. Clinical trials in psoriasis patients have documented significant reductions in serum TNF-α, IL-6, IL-1β, CRP, and LPS following probiotic supplementation. These are some of the same targets that biologic therapies address—making probiotics a genuinely complementary, not merely peripheral, intervention.^[11]

4. Restoring SCFA-producing bacterial populations. By replenishing depleted Bifidobacterium and Lactobacillus populations, probiotic supplementation can increase SCFA production, which in turn suppresses the IL-23/Th17 axis. Some studies have specifically documented reductions in the pro-inflammatory genera Micromonospora and Rhodococcus, alongside increases in beneficial Collinsella and Lactobacillus, following probiotic treatment in psoriasis patients.^[3]

Clinical Evidence: What the Trials Show

The clinical database for probiotics in psoriasis, while still growing, has matured significantly over the past five years. Multiple randomized controlled trials, supplemented by systematic reviews and meta-analyses, now provide a reasonably clear picture of the effect size and the types of strains most likely to be effective.

Meta-Analyses: The Big Picture

A 2024 systematic review and meta-analysis published in the Journal of Cosmetic Dermatology pooled data from five randomized controlled trials in adults with psoriasis. The results showed PASI scores were significantly lower in the probiotic supplementation group (SMD = −1.40, 95% CI: −2.63 to −0.17, p < 0.00001). The analysis included studies using formulas containing Lactobacillus rhamnosus, Bifidobacterium spp., Lactobacillus acidophilus, and Streptococcus thermophilus. The researchers concluded that probiotic supplementation could represent a new treatment option for psoriasis.^[2]

A separate 2024 meta-analysis published in Frontiers in Medicine confirmed these findings, reporting that PASI decreased more significantly from baseline in the probiotic group than in the placebo group, and that the proportion of patients achieving ≥75% PASI reduction showed an increasing trend in the probiotic group. Additionally, serum CRP levels fell significantly in probiotic-treated patients compared with placebo.^[12]

Key Randomized Controlled Trials

The individual trial data is equally instructive. A 2021 randomized, double-blind, placebo-controlled trial in 50 psoriasis patients administered a probiotic capsule containing Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, and Bifidobacterium longum (1.8 × 10⁹ CFU) for 8 weeks. At week 8, mean PASI scores dropped from 10.65 ± 5.12 to 5.39 ± 2.73 in the probiotic group, while scores in the placebo group increased. 40% of patients in the probiotic group reached PASI 50 and 24% achieved PASI 75. Significant reductions were also observed in hs-CRP, IL-6, and malondialdehyde—an oxidative stress marker—in the probiotic group (all p < 0.05).^[11]

A 12-week double-blind, placebo-controlled trial in 90 psoriasis patients using a formula containing Bifidobacterium longum, B. lactis, and Lactobacillus rhamnosus (1 × 10⁹ CFU) alongside topical anti-psoriatic treatment found that 66.7% of patients in the probiotic group achieved PASI 75 compared with 41.9% in the placebo group (p < 0.05). A 6-month follow-up showed a significantly lower risk of disease relapse in the probiotic group. Notably, the probiotic treatment was also associated with elimination of the pathogenic genus Rhodococcus and an increase in Collinsella and Lactobacillus—beneficial shifts in gut microbiome composition.^[3]

A landmark 2013 randomized, double-blind, placebo-controlled trial published in Gut Microbes specifically assessed the systemic immunological effects of Bifidobacterium infantis 35624 in psoriasis patients not receiving anti-psoriatic treatment. After 6–8 weeks of supplementation, plasma CRP and TNF-α were significantly reduced in the B. infantis group compared to placebo—demonstrating that a single probiotic strain can modulate systemic inflammatory markers in a non-gastrointestinal autoimmune condition. This was one of the first studies to demonstrate probiotic immunomodulation beyond the mucosa in psoriasis.^[4]

A 2022 RCT used a multi-strain probiotic (1.6 × 10⁹ CFU) for 8 weeks in psoriasis patients and documented a 51% reduction in PASI scores in the probiotic group (vs. no change in placebo, p = 0.049), alongside significant improvements in quality of life and significant reductions in serum lipopolysaccharides, hs-CRP, and IL-1β.^[13]

Best Probiotic Strains for Psoriasis: What's in MicroBiome Restore

The strains with the most direct clinical evidence in psoriasis research are those most consistently found in successful multi-strain trials: members of the Bifidobacterium and Lactobacillus genera, particularly those with demonstrated effects on the inflammatory markers most relevant to psoriatic disease. Here's how the research maps onto the strains in MicroBiome Restore.

Bifidobacterium longum subsp. longum — Psoriasis Severity and Relapse Prevention

Bifidobacterium longum is one of the most consistently studied strains in psoriasis RCTs. In the 12-week trial described above, a formula combining B. longum, B. lactis, and L. rhamnosus produced PASI 75 response in 66.7% of the treatment group, with significantly lower relapse rates at 6-month follow-up compared with placebo.^[3] Animal studies on the related subspecies B. longum CECT 7347 in the same combination have consistently documented microbiome normalization alongside clinical improvement. Our Bifidobacterium longum overview covers the broader clinical evidence for this strain in gut health contexts.

Bifidobacterium infantis — Systemic Inflammation Reduction

Bifidobacterium infantis has unique immunological properties that make it particularly relevant to autoimmune and inflammatory conditions. In a direct psoriasis trial, B. infantis 35624 administered for 6–8 weeks produced significant reductions in plasma CRP and TNF-α compared with placebo in psoriasis patients—both central inflammatory drivers in the disease.^[4] The mechanism appears to involve induction of peripheral regulatory T cells, which counteract the Th17-driven inflammation characteristic of psoriatic disease. You can read more about the research on Bifidobacterium infantis benefits across inflammatory conditions.

Bifidobacterium lactis — Multi-Strain Synergy in Psoriasis Trials

Bifidobacterium lactis has appeared in multiple psoriasis RCTs as part of effective multi-strain formulas. In both the 2021 8-week trial (with L. acidophilus, B. bifidum, B. longum) and the 12-week trial (with B. longum and L. rhamnosus), B. lactis was a consistent component of formulas that produced significant PASI improvements and reduced inflammatory biomarkers.^[11] Explore the broader clinical research on Bifidobacterium lactis gut health benefits.

Bifidobacterium bifidum — Inflammatory Marker Reduction

Bifidobacterium bifidum was included in the 2021 psoriasis RCT that documented significant PASI score reduction alongside drops in hs-CRP, IL-6, and oxidative stress markers. Like other Bifidobacterium species, it supports barrier integrity and mucosal immunity—both relevant given the leaky gut phenotype documented in psoriatic disease.^[11] For an overview of what happens when Bifidobacterium populations are deficient, see our article on Bifidobacterium deficiency and gut health.

Lactobacillus rhamnosus — Immune Regulation and Arthritis Attenuation

Lactobacillus rhamnosus has a well-established track record in immune modulation and has been documented to attenuate experimental arthritis in animal models through direct effects on intestinal permeability and immune homeostasis.^[10] It is a component of the multi-strain psoriasis formula that produced PASI 75 in 66.7% of patients in the most cited 12-week trial, and it appeared in multiple formulas analyzed in the 2024 meta-analysis. When used alone as a single-strain intervention in psoriasis, results have been mixed—reinforcing the value of multi-strain over single-strain approaches. See the full rundown on Lactobacillus rhamnosus benefits.

Lactobacillus acidophilus — Consistent Presence in Effective Psoriasis Formulas

Lactobacillus acidophilus is among the most established Lactobacillus strains in clinical research, appearing in the 2021 psoriasis RCT alongside three Bifidobacterium species in a formula that produced clinically significant PASI reductions and inflammatory marker improvements. It was also included in the multi-strain synbiotic formula evaluated in a psoriasis RCT that documented significant improvements in serum electrolyte absorption—a downstream marker of improved gastrointestinal function.^[7] Explore the comprehensive evidence on Lactobacillus acidophilus dosage and clinical guidelines.

Lactobacillus plantarum — Gut Barrier and Anti-Inflammatory Effects

Lactobacillus plantarum is a robust colonizer of the intestinal tract with well-documented effects on intestinal barrier function, tight junction integrity, and systemic anti-inflammatory activity. In psoriasis-related research, Lactobacillus pentosus—a closely related species—was shown to decrease psoriatic lesions and levels of pro-inflammatory cytokines in preclinical models. L. plantarum's barrier-protective properties are particularly relevant given the elevated intestinal permeability documented in psoriasis and PsA patients. Explore the full research on Lactobacillus plantarum health benefits, including its anti-inflammatory and antioxidant effects.

Lactobacillus paracasei, Lactobacillus reuteri, Bifidobacterium breve

In preclinical models of imiquimod-induced psoriasis, L. paracasei CCFM1074, L. reuteri CCFM1132, and B. breve CCFM1078 all demonstrated significant reductions in erythema, scaling, and skin thickening, along with suppression of the IL-23/Th17 inflammatory axis.^[7] These strains also elevated acetate and propionate levels—the SCFAs that inversely correlate with IL-17 and IL-23 concentrations. While these are preclinical findings, they provide mechanistic plausibility for their inclusion in a comprehensive psoriasis-supportive probiotic formula. Explore the broader benefits of Lactobacillus reuteri.

Streptococcus thermophilus

Streptococcus thermophilus appeared in the synbiotic formulas reviewed in psoriasis research, and was specifically named alongside Lactobacillus and Bifidobacterium as a maternal supplement that influences infant immune development in the context of inflammatory disease prevention.^[14] Its fermentation activity and barrier-supporting properties contribute to the overall ecosystem effect of multi-strain probiotic formulas. Learn more about the clinical benefits of Streptococcus thermophilus.

Probiotics and Psoriatic Arthritis: The Joint Connection

Psoriatic arthritis represents a distinct but overlapping challenge. Up to 30% of people with psoriasis develop PsA, and the gut microbiome plays a role in this progression that is now being actively researched. The gut dysbiosis in PsA closely resembles that seen in IBD, and a landmark study by Scher et al. found distinct reductions in Ruminococcus and Akkermansia muciniphila in PsA patients—species that produce SCFAs from mucin and help suppress Th17 activity.^[5]

A 12-week open-label pilot study in PsA patients (published in Nutrients, 2020) demonstrated that elevated fecal zonulin—an intestinal permeability marker—was present in all 10 patients at baseline and significantly correlated with peripheral Th17 cell frequency. Following 12 weeks of Bifidobacterium and Lactobacillus probiotic supplementation, both disease activity scores and gut permeability markers improved significantly. The correlation between permeability and Th17 activity also weakened after treatment, suggesting the probiotic intervention was breaking a mechanistic link between leaky gut and joint inflammation.^[5]

A 2023 abstract at the American College of Rheumatology annual meeting reported preliminary results of a double-blind RCT (NCT04588623) evaluating a multi-strain Bifidobacterium and Lactobacillus probiotic in PsA patients with moderate disease activity. Patients in the probiotic arm showed improvements in disease activity scores and immune cell composition compared to placebo at 12 weeks, with further gains seen when the placebo group crossed over to probiotic treatment at week 24.^[15]

A 2025 pilot double-blind RCT published in Food Science & Nutrition also examined immunomodulatory effects of multi-strain probiotic capsules in PsA, documenting effects on immune cell populations consistent with reduced autoinflammatory activity. The authors concluded that gut dysbiosis is a clinically relevant contributing factor to PsA pathogenesis and that probiotic supplementation warrants further investigation in larger trials.^[16]

What to Look for in a Probiotic if You Have Psoriasis

Not all probiotics are created equal, and the psoriasis clinical data is specific enough to draw meaningful conclusions about what characteristics matter most.

Multi-Strain Diversity Covering Both Bifidobacterium and Lactobacillus

Every clinical trial in psoriasis that demonstrated significant PASI improvement used a multi-strain formula spanning both Bifidobacterium and Lactobacillus genera. Single-strain interventions—including single-strain L. rhamnosus over six months—have not consistently produced statistically significant PASI changes.^[2] The additive or synergistic effects of multiple strains targeting different aspects of gut immune homeostasis appear to be important. A formula like MicroBiome Restore that includes 26 strains across multiple genera provides broad-spectrum coverage—including every strain with direct clinical evidence in psoriasis research.

Clean Formulation: Fillers That Undermine Gut Health

A frequently overlooked issue in probiotic selection is inactive ingredients. Many commercial probiotic formulas contain microcrystalline cellulose (MCC) as a bulking agent—a compound with documented effects on intestinal permeability and mucosal immune activation that runs directly counter to the goals of probiotic supplementation for psoriasis. Similarly, magnesium stearate—a ubiquitous flow agent—has been shown in vitro to suppress T cell function and impair biofilm formation by beneficial bacteria. These are not theoretical concerns. When the entire rationale for taking a probiotic involves restoring gut barrier integrity and modulating immune activity, it matters what else is in the capsule. Learning to read supplement labels for hidden fillers is a practical first step. Our deep-dive on why flow agents and fillers compromise probiotic effectiveness covers this in more detail.

Capsule Material

Pullulan capsules—used in MicroBiome Restore—are derived from a naturally fermented polysaccharide with prebiotic activity, and they provide a degree of oxygen and moisture barrier that supports bacterial viability. By contrast, hypromellose (HPMC) capsules, the most common synthetic alternative, provide no prebiotic benefit and require chemical processing. For a psoriasis patient specifically targeting gut health outcomes, capsule material is part of the total formula equation.

Prebiotic Support for Probiotic Effectiveness

Probiotics are only as effective as the environment they are placed in. Without prebiotic fibers to feed beneficial bacteria, colonization is transient. MicroBiome Restore includes nine organic prebiotics—among them Jerusalem artichoke (a concentrated source of inulin-type fructans that selectively stimulate Bifidobacterium growth) and acacia fiber (which supports both Bifidobacterium and Lactobacillus populations while being notably well tolerated by sensitive digestive systems). Maitake mushroom, also included, contributes beta-glucans with direct immune-modulating properties relevant to inflammatory disease. The prebiotic component of a synbiotic formula is not a marketing add-on—it is functionally integral to the clinical outcomes the research documents.

Frequently Asked Questions

The Gut-Skin Connection: What It Means for Managing Psoriasis

The science connecting gut microbiome dysbiosis to psoriasis and psoriatic arthritis has moved from speculative to substantiated. A consistent pattern of depleted Bifidobacterium and Lactobacillus populations, elevated gut permeability, and dysregulated SCFA production runs through the gut microbiome profiles of people with both conditions—and these disruptions feed directly into the inflammatory pathways that manifest on the skin and in the joints.

Clinical trials using multi-strain probiotics containing Bifidobacterium longum, B. lactis, B. infantis, B. bifidum, L. rhamnosus, and L. acidophilus have produced statistically significant and clinically meaningful PASI reductions, lower inflammatory biomarkers (CRP, TNF-α, IL-6, LPS), improved quality of life scores, and reduced disease relapse rates in psoriasis patients. For psoriatic arthritis, early-stage evidence points to improvements in gut permeability and disease activity with probiotic supplementation, with larger trials currently underway.

The practical implication is straightforward: if you have psoriasis or PsA, your gut microbiome matters—and a well-formulated, multi-strain, filler-free probiotic is one of the most evidence-aligned tools available to support it. To see how these strains come together in one formula, explore our complete guide to MicroBiome Restore or learn more about the broader gut-skin axis and inflammatory skin conditions. For those interested in the relationship between gut health and systemic inflammation more broadly, our article on probiotics for leaky gut and barrier repair covers the intestinal permeability research in depth.